J. P. Díaz-Madriz, Esteban Zavaleta‐Monestel, Carolina Rojas-Chinchilla, Sebastián Arguedas‐Chacón, Bruno Serrano-Arias, Mery Alejandra Ferreto-Meza, Betzy María Romero-Chavarría, Priscila Zumbado-Amerling, A. Vásquez-Mendoza, Karla Sofia Gutiérrez-González, César Rodríguez
(1) Background: Given the widespread use of Alkalihalobacillus clausii (A. clausii) as a probiotic in recent decades and the detection of bacteremia cases in a group of patients, we sought to analyze cases of A. clausii bacteremia following oral probiotic use (2) Methods: A retrospective observational study was conducted at a private hospital in San Jose, Costa Rica. Cases of bacteremia caused by A. clausii confirmed by the microbiology laboratory were analyzed in patients who received oral treatment with this probiotic between January 2020 and January 2022. In addition, an isolate (HCB-AC2) was compared through whole genome sequencing to demonstrate the correlation of bacteremia and A. clausii. Possible vulnerability factors related to the development of this condition were determined. (3) Results: Four cases were identified in this hospital over 2 years. Genomic analysis of isolate HCB-AC2, using two different methods, showed identical results. This indicates that HCB-AC2 is genomically identical to ENTpro and the Enterogermina® reference genome. The median age was 71 years, and all patients had some degree of immunosuppression. All patients met at least three sepsis criteria at the time of bacterial identification. Most patients were treated with vancomycin and levofloxacin. Three of the identified patients died. (4) Conclusion: A. clausii can be used as a probiotic, but caution is advised when used in immunosuppressed and elderly patients. These findings align with those reported in similar case studies.
{"title":"Bacteremia Following Alkalihalobacillus clausii (Formerly Bacillus clausii) Administration in Immunosuppressed Adults: A Case Series","authors":"J. P. Díaz-Madriz, Esteban Zavaleta‐Monestel, Carolina Rojas-Chinchilla, Sebastián Arguedas‐Chacón, Bruno Serrano-Arias, Mery Alejandra Ferreto-Meza, Betzy María Romero-Chavarría, Priscila Zumbado-Amerling, A. Vásquez-Mendoza, Karla Sofia Gutiérrez-González, César Rodríguez","doi":"10.3390/bacteria2040014","DOIUrl":"https://doi.org/10.3390/bacteria2040014","url":null,"abstract":"(1) Background: Given the widespread use of Alkalihalobacillus clausii (A. clausii) as a probiotic in recent decades and the detection of bacteremia cases in a group of patients, we sought to analyze cases of A. clausii bacteremia following oral probiotic use (2) Methods: A retrospective observational study was conducted at a private hospital in San Jose, Costa Rica. Cases of bacteremia caused by A. clausii confirmed by the microbiology laboratory were analyzed in patients who received oral treatment with this probiotic between January 2020 and January 2022. In addition, an isolate (HCB-AC2) was compared through whole genome sequencing to demonstrate the correlation of bacteremia and A. clausii. Possible vulnerability factors related to the development of this condition were determined. (3) Results: Four cases were identified in this hospital over 2 years. Genomic analysis of isolate HCB-AC2, using two different methods, showed identical results. This indicates that HCB-AC2 is genomically identical to ENTpro and the Enterogermina® reference genome. The median age was 71 years, and all patients had some degree of immunosuppression. All patients met at least three sepsis criteria at the time of bacterial identification. Most patients were treated with vancomycin and levofloxacin. Three of the identified patients died. (4) Conclusion: A. clausii can be used as a probiotic, but caution is advised when used in immunosuppressed and elderly patients. These findings align with those reported in similar case studies.","PeriodicalId":502262,"journal":{"name":"Bacteria","volume":"146 1-3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139183111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Klebsiella pneumoniae, a Gram-negative pathogen, poses a significant threat as a cause of community- and hospital-acquired infections worldwide. The emergence of multidrug-resistant strains, particularly in nosocomial settings, has further complicated the management of these infections. This study aimed to investigate the culture identification and antibiogram of K. pneumoniae isolated from sputum samples collected in various districts in Mardan, Khyber Pakhtunkhwa, Pakistan. A total of 16 sputum samples were collected from patients at the Mardan Medical Complex. Standard microbiological techniques were employed to identify K. pneumoniae, and the antibiotic susceptibility testing was performed using the Kirby–Bauer disc diffusion method, following CLSI guidelines. Among the confirmed K. pneumoniae isolates, approximately 50% were found to be multidrug-resistant. The results indicated resistance to several antibiotics, including vancomycin (30 g), amikacin (30 g), chloramphenicol (30 g), amoxicillin (30 g), and ticarcillin (75 g), while being susceptible to meropenem (10 g), piperacillin (100 g), and tazobactam (110 g). A bioinformatics analysis was also conducted to gain deeper insights into the resistance patterns and potential clustering of isolates. This comprehensive study provides valuable information on the epidemiological trends and antimicrobial susceptibility profile of K. pneumoniae in the region. The findings of this study highlight the urgent need for antimicrobial stewardship programs to combat the rising challenge of antibiotic resistance. Understanding the resistance landscape of K. pneumoniae can guide healthcare professionals in selecting appropriate antibiotics and improving patient outcomes. These data can contribute to the formulation of local antibiotic policies and assist clinicians in making rational choices for antibiotic therapy.
{"title":"Comprehensive Analysis of Klebsiella pneumoniae Culture Identification and Antibiogram: Implications for Antimicrobial Susceptibility Patterns from Sputum Samples in Mardan, Khyber Pakhtunkhwa, Pakistan","authors":"Ruby Khan, Saima Wali, Bakht Pari","doi":"10.3390/bacteria2040012","DOIUrl":"https://doi.org/10.3390/bacteria2040012","url":null,"abstract":"Klebsiella pneumoniae, a Gram-negative pathogen, poses a significant threat as a cause of community- and hospital-acquired infections worldwide. The emergence of multidrug-resistant strains, particularly in nosocomial settings, has further complicated the management of these infections. This study aimed to investigate the culture identification and antibiogram of K. pneumoniae isolated from sputum samples collected in various districts in Mardan, Khyber Pakhtunkhwa, Pakistan. A total of 16 sputum samples were collected from patients at the Mardan Medical Complex. Standard microbiological techniques were employed to identify K. pneumoniae, and the antibiotic susceptibility testing was performed using the Kirby–Bauer disc diffusion method, following CLSI guidelines. Among the confirmed K. pneumoniae isolates, approximately 50% were found to be multidrug-resistant. The results indicated resistance to several antibiotics, including vancomycin (30 g), amikacin (30 g), chloramphenicol (30 g), amoxicillin (30 g), and ticarcillin (75 g), while being susceptible to meropenem (10 g), piperacillin (100 g), and tazobactam (110 g). A bioinformatics analysis was also conducted to gain deeper insights into the resistance patterns and potential clustering of isolates. This comprehensive study provides valuable information on the epidemiological trends and antimicrobial susceptibility profile of K. pneumoniae in the region. The findings of this study highlight the urgent need for antimicrobial stewardship programs to combat the rising challenge of antibiotic resistance. Understanding the resistance landscape of K. pneumoniae can guide healthcare professionals in selecting appropriate antibiotics and improving patient outcomes. These data can contribute to the formulation of local antibiotic policies and assist clinicians in making rational choices for antibiotic therapy.","PeriodicalId":502262,"journal":{"name":"Bacteria","volume":"C-27 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139271103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：